These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 39143551)

  • 1. Circulating interleukin-8 and osteopontin are promising biomarkers of clinical outcomes in advanced melanoma patients treated with targeted therapy.
    Levati L; Tabolacci C; Facchiano A; Facchiano F; Alvino E; Antonini Cappellini GC; Scala E; Bonmassar L; Caporali S; Lacal PM; Bresin A; De Galitiis F; Russo G; D'Atri S
    J Exp Clin Cancer Res; 2024 Aug; 43(1):226. PubMed ID: 39143551
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating miR-1246 and miR-485-3p as Promising Biomarkers of Clinical Response and Outcome in Melanoma Patients Treated with Targeted Therapy.
    Levati L; Bassi C; Mastroeni S; Lupini L; Antonini Cappellini GC; Bonmassar L; Alvino E; Caporali S; Lacal PM; Narducci MG; Molineris I; De Galitiis F; Negrini M; Russo G; D'Atri S
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954369
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study.
    Syeda MM; Wiggins JM; Corless BC; Long GV; Flaherty KT; Schadendorf D; Nathan PD; Robert C; Ribas A; Davies MA; Grob JJ; Gasal E; Squires M; Marker M; Garrett J; Brase JC; Polsky D
    Lancet Oncol; 2021 Mar; 22(3):370-380. PubMed ID: 33587894
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients.
    Pasello G; Fabricio ASC; Del Bianco P; Salizzato V; Favaretto A; Piccin L; Zustovich F; Fabozzi A; De Rossi C; Pigozzo J; De Nuzzo M; Cappelletto E; Bonanno L; Palleschi D; De Salvo GL; Guarneri V; Gion M; Chiarion-Sileni V
    J Transl Med; 2024 Mar; 22(1):242. PubMed ID: 38443899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of total metabolic tumour volume and therapy-response assessment by [
    Annovazzi A; Ferraresi V; Rea S; Russillo M; Renna D; Carpano S; Sciuto R
    Eur Radiol; 2022 May; 32(5):3398-3407. PubMed ID: 34779873
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of different exosomes' protein expression in pancreatic ductal carcinoma patients treated with standard first line palliative chemotherapy.
    Giampieri R; Piva F; Occhipinti G; Bittoni A; Righetti A; Pagliaretta S; Murrone A; Bianchi F; Amantini C; Giulietti M; Ricci G; Principato G; Santoni G; Berardi R; Cascinu S
    PLoS One; 2019; 14(5):e0215990. PubMed ID: 31048929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. EPSILoN: A Prognostic Score Using Clinical and Blood Biomarkers in Advanced Non-Small-cell Lung Cancer Treated With Immunotherapy.
    Prelaj A; Rebuzzi SE; Pizzutilo P; Bilancia M; Montrone M; Pesola F; Longo V; Del Bene G; Lapadula V; Cassano F; Petrillo P; Bafunno D; Varesano N; Lamorgese V; Mastrandrea A; Ricci D; Catino A; Galetta D
    Clin Lung Cancer; 2020 Jul; 21(4):365-377.e5. PubMed ID: 32245624
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased visceral to subcutaneous fat ratio is associated with decreased overall survival in patients with metastatic melanoma receiving anti-angiogenic therapy.
    Grignol VP; Smith AD; Shlapak D; Zhang X; Del Campo SM; Carson WE
    Surg Oncol; 2015 Dec; 24(4):353-8. PubMed ID: 26690825
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic treatments for metastatic cutaneous melanoma.
    Pasquali S; Hadjinicolaou AV; Chiarion Sileni V; Rossi CR; Mocellin S
    Cochrane Database Syst Rev; 2018 Feb; 2(2):CD011123. PubMed ID: 29405038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials.
    Hauschild A; Larkin J; Ribas A; Dréno B; Flaherty KT; Ascierto PA; Lewis KD; McKenna E; Zhu Q; Mun Y; McArthur GA
    JAMA Oncol; 2018 Oct; 4(10):1382-1388. PubMed ID: 30073321
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations are associated with longer progression-free and overall survival in patients with BRAF-mutant melanoma receiving BRAF and MEK inhibitor therapy.
    Thielmann CM; Matull J; Zaremba A; Murali R; Chorti E; Lodde G; Jansen P; Herbst R; Terheyden P; Utikal J; Pföhler C; Ulrich J; Kreuter A; Mohr P; Gutzmer R; Meier F; Dippel E; Weichenthal M; Kretz J; Möller I; Sucker A; Paschen A; Livingstone E; Zimmer L; Hadaschik E; Ugurel S; Schadendorf D; Griewank KG
    Eur J Cancer; 2022 Jan; 161():99-107. PubMed ID: 34936949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Circulating tumour DNA predicts response to anti-PD1 antibodies in metastatic melanoma.
    Lee JH; Long GV; Boyd S; Lo S; Menzies AM; Tembe V; Guminski A; Jakrot V; Scolyer RA; Mann GJ; Kefford RF; Carlino MS; Rizos H
    Ann Oncol; 2017 May; 28(5):1130-1136. PubMed ID: 28327969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations.
    Ascierto PA; Capone M; Grimaldi AM; Mallardo D; Simeone E; Madonna G; Roder H; Meyer K; Asmellash S; Oliveira C; Roder J; Grigorieva J
    J Immunother Cancer; 2019 Mar; 7(1):91. PubMed ID: 30925943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
    Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
    Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors.
    Menzies AM; Wilmott JS; Drummond M; Lo S; Lyle M; Chan MM; Thompson JF; Guminski A; Carlino MS; Scolyer RA; Kefford RF; Long GV
    Cancer; 2015 Nov; 121(21):3826-35. PubMed ID: 26218930
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neutrophil to Lymphocyte Ratio is Associated With Outcome During Ipilimumab Treatment.
    Cassidy MR; Wolchok RE; Zheng J; Panageas KS; Wolchok JD; Coit D; Postow MA; Ariyan C
    EBioMedicine; 2017 Apr; 18():56-61. PubMed ID: 28356222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. D-dimers in malignant melanoma: Association with prognosis and dynamic variation in disease progress.
    Desch A; Gebhardt C; Utikal J; Schneider SW
    Int J Cancer; 2017 Feb; 140(4):914-921. PubMed ID: 27813063
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Undetectable circulating tumor DNA (ctDNA) levels correlate with favorable outcome in metastatic melanoma patients treated with anti-PD1 therapy.
    Seremet T; Jansen Y; Planken S; Njimi H; Delaunoy M; El Housni H; Awada G; Schwarze JK; Keyaerts M; Everaert H; Lienard D; Del Marmol V; Heimann P; Neyns B
    J Transl Med; 2019 Sep; 17(1):303. PubMed ID: 31488153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of serum osteopontin level and gene polymorphism as biomarkers: analyses from the Nordic Adjuvant Interferon alpha Melanoma trial.
    Prasmickaite L; Berge G; Bettum IJ; Aamdal S; Hansson J; Bastholt L; Øijordsbakken M; Boye K; Mælandsmo GM
    Cancer Immunol Immunother; 2015 Jun; 64(6):769-76. PubMed ID: 25832001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.